New CF Patient Subset For Vertex With Kaftrio's EU Approval
Opportunity Opens Following EU Approval Of Triple Combination
EU approval came quicker than expected for Vertex’s new triple-combination CFTR drug, Kaftrio.
You may also be interested in...
While Vertex appears to have the cystic fibrosis market covered with its CFTR modulators, Enterprise has been exploring another channel, TMEM16A, in the hope of developing compounds that could possibly be used by everybody with the lethal genetic disease.
Only nine weeks after US approval, Trikafta, which in theory can treat 90% of all patients with cystic fibrosis, is already Vertex's top-selling medicine.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements